.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The Idiopathic Intracranial Hypertension Treatment Trial evaluated acetazolamide plus a low-sodium weight-reduction diet versus placebo plus diet in patients with idiopathic intracranial hypertension and mild visual loss. Acetazolamide produced a modest but statistically significant improvement in the primary visual-field outcome at six months, accompanied by improvements in papilledema and quality of life in the broader trial. The benefit is clinically meaningful because IIH can cause irreversible optic-nerve damage if raised intracranial pressure is not controlled. The trial also reinforces that weight reduction is an important component of management rather than an optional adjunct. For HCPs, treatment should be individualised according to visual function, papilledema severity, tolerability and the patient's ability to sustain weight loss. Acetazolamide can cause metabolic, gastrointestinal and renal adverse effects, so monitoring and dose titration are necessary. The evidence directly supports AIOC's neuro-ophthalmology focus on idiopathic intracranial hypertension and optic-nerve protection.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The Idiopathic Intracranial Hypertension Treatment Trial evaluated acetazolamide plus a low-sodium weight-reduction diet versus placebo plus diet in patients with idiopathic intracranial hypertension and mild visual loss. Acetazolamide produced a modest but statistically significant improvement in the primary visual-field outcome at six months, accompanied by improvements in papilledema and quality of life in the broader trial. The benefit is clinically meaningful because IIH can cause irreversible optic-nerve damage if raised intracranial pressure is not controlled. The trial also reinforces that weight reduction is an important component of management rather than an optional adjunct. For HCPs, treatment should be individualised according to visual function, papilledema severity, tolerability and the patient's ability to sustain weight loss. Acetazolamide can cause metabolic, gastrointestinal and renal adverse effects, so monitoring and dose titration are necessary. The evidence directly supports AIOC's neuro-ophthalmology focus on idiopathic intracranial hypertension and optic-nerve protection.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
